Extended mantle radiation therapy for pathologic stage I and II XXXX .

@entity1 @entity137 @entity390 @entity391 @entity958 @entity236 @entity978
Between 1968 and 1983, 135 @entity1 with pathologic stage (PS) I and II @entity978 were treated with extended mantle radiation technique (EMRT) at Michael Reese Hospital and the University of Chicago Center for Radiation Therapy. EMRT combines both standard mantle and para-aorta fields (M-PA) in one port. Actuarial disease-free survival at 5 and 10 years was 82.5%. Actuarial overall survival was 96% and 83% at 5 and 10 years, respectively. Acute complications were evaluated in 112 @entity1 available for analysis. Severe @entity390 and @entity391 occurred in 13%, weight loss of greater than 10% of body weight in 19%, and acute hematologic @entity137 in 4% of @entity1 . @entity236 was transient and did not interfere with subsequent delivery of salvage treatment with either chemotherapy or radiation therapy in 22 @entity1 who relapsed. The cost of EMRT is 40% lower than the cost of treatment with M-PA. The median treatment time was 38 days, 33% less than the 56 days for M-PA field assuming no interruptions. These results suggest that the @entity958 is a safe and effective treatment tolerated by most @entity1 . The advantages of this method are eliminating the possibility of technical error of matching between mantle and para-aortic field, decreasing overall treatment time, and reducing the cost.
